PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Daridorexant - Insomnia in adults

PAD Profile : Daridorexant - Insomnia in adults

Brand Names Include :
Quviviq

Traffic Light Status

Status 1 of 1.

Status :
Blue
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
07 February 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves daridorexant for the treatment of long-term insomnia in line with NICE TA922

A BLUE traffic light status has been agreed after Cognitive Behavioural Therapy for insomnia (CBTi) where available.

Specialist clinics will need to provide the medicines for the first 4 months (if clinically indicated), providing a review at 3 months to confirm whether treatment should be continued, and prescribing an extra month for those who will continue on treatment to allow for transfer of care to Primary Care

The length of treatment should be as short as possible.

Associated BNF Codes

04. Central Nervous System
04.01.01. Hypnotics
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More